Growth Hormone Axis · GHRH analog + GH secretagogue (compounded)
CJC-1295 + Ipamorelin
- Drug class
- GHRH analog + GH secretagogue (compounded)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What CJC-1295 + Ipamorelin is studied for
- Growth hormone axis support
- Sleep quality and slow-wave sleep
- Body composition and recovery
- Adult IGF-1 optimization (off-label)
Mechanism of action
CJC-1295 (mod-GRF 1-29 or DAC variant) binds GHRH receptors to amplify endogenous GH release. Ipamorelin binds the ghrelin/GHSR receptor to trigger a clean GH pulse — selectively, without cortisol or prolactin rise (unlike older GHRPs).
Frequently asked questions
How is CJC-1295 + Ipamorelin dosed?
Typical research dosing is 100–300 mcg of each, subcutaneously, 1–3x daily — most commonly at bedtime to align with the largest natural GH pulse. Always under clinician supervision.
Will it shut down natural GH?
Unlike exogenous HGH, GHRH + GHRP combinations work with the pituitary, preserving negative-feedback safety. Cycling is still commonly recommended.
What is the difference between CJC with DAC and no DAC?
No DAC ("Mod GRF 1-29") has a short half-life — clean pulses. With DAC (drug affinity complex) extends half-life to ~8 days, producing sustained GH elevation rather than pulses. Most clinical protocols favor no-DAC for safety.
Side effects?
Injection-site reactions, transient flushing, increased appetite, occasional tingling. Long-term human safety data is limited.
Build the CJC-1295 + Ipamorelin protocol stack
Research protocols commonly pair CJC-1295 + Ipamorelin with the peptides below. Add all three vials to unlock the bundle discount at checkout.
Related peptides in Growth Hormone Axis
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- When to start HRTJournal
- Menopause HRT serviceMedication
- Complete menopause guideJournal
